A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
| Condition(s) | Carcinoma, Non-small-Cell Lung |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy. |
| Who can participate | Inclusion Criteria: * Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC) * Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor \[EGFR\], anaplastic lymphoma kinase \[ALK\], c-ros oncogene 1 \[ROS1\], v-raf murine sarcoma viral oncogene homolog B1 \[BRAF\]) must have received all approved targeted therapies and have progressed * Part 2: No targetable mutations (for example, EGFR \[epidermal growth factor receptor\], ALK \[anaplastic lymphoma kinase\], ROS1\[c-ros oncogene 1\], and BRAF \[B-Raf proto-oncogene, serine/threonine kinase\]) * Part 1 and Cohort A of part 2: Must have been treated with (a) anti-programmed death protein 1 (anti-PD-1) or programmed cell death ligand 1 (PD-L1) t |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Johnson & Johnson Enterprise Innovation Inc. |
| Locations | Newnan, Georgia, United States; Hackensack, New Jersey, United States; Buffalo, New York, United States; New York, New York, United States; Portland, Oregon, United States; Philadelphia, Pennsylvania, United States (+9 more sites) |
| Start date | 2023-11-27 |
| NCT ID | NCT06116786 |
| Official listing | https://clinicaltrials.gov/study/NCT06116786 |